Assenagon Asset Management
LFCR icon

Assenagon Asset Management’s Lifecore Biomedical LFCR Stock Holding History

Assenagon Asset Management’s Portfolio LFCR Stock Details LFCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-23,852
Closed -$127K – 1454
2024
Q1 		$127K Hold
23,852
– – ﹤0.01% 1342
2023
Q4 		$148K Hold
23,852
– – ﹤0.01% 1379
2023
Q3 		$180K Sell
23,852
-51,539
-68% -$471K ﹤0.01% 1343
2023
Q2 		$729K Hold
75,391
– – ﹤0.01% 1050
2023
Q1 		$285K Hold
75,391
– – ﹤0.01% 1311
2022
Q4 		$489K Sell
75,391
-73,412
-49% -$605K ﹤0.01% 1179
2022
Q3 		$1.32M Sell
148,803
-107,006
-42% -$1.09M 0.01% 862
2022
Q2 		$2.55M Sell
255,809
-98,716
-28% -$977K 0.01% 743
2022
Q1 		$4.11M Sell
354,525
-100,465
-22% -$1.12M 0.01% 586
2021
Q4 		$5.05M Buy
454,990
+439,339
+2,807% +$4.26M 0.01% 512
2021
Q3 		$144K Buy
+15,651
New +$170K ﹤0.01% 1248

Other funds holding LFCR

WC
Wynnefield Capital New York $148M AUM 32.71% 1-Year Est. Return
2L
22NW LP Seattle, Washington $146M AUM 29.83% 1-Year Est. Return
LPAM
Legion Partners Asset Management Los Angeles, California $138M AUM 53.69% 1-Year Est. Return
GRIM
Greenhaven Road Investment Management Greenwich, Connecticut $145M AUM 13.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
3C
325 Capital New York $274M AUM 49.96% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VWA
Visionary Wealth Advisors O'fallon, Illinois $2.26B AUM 19.48% 1-Year Est. Return

Assenagon Asset Management's LFCR Position: Q2 2024 in Review

Assenagon Asset Management sold out of Lifecore Biomedical (LFCR) in Q2 2024, closing a stake of 23,852 shares — an estimated $127K sold.

Assenagon Asset Management first reported a position in LFCR in Q3 2021 and held it in 11 quarters. The position peaked at $5.05M in Q4 2021. 75 funds tracked by Wall St. Rank hold LFCR as of Q2 2024.

  • Assenagon Asset Management reported no remaining Lifecore Biomedical position as of Q2 2024 after selling out during the quarter.
  • Assenagon Asset Management sold 23,852 Lifecore Biomedical shares in Q2 2024, an estimated $127K.
  • Assenagon Asset Management first reported a position in Lifecore Biomedical in Q3 2021 and held it in 11 quarters.
  • Assenagon Asset Management's Lifecore Biomedical position peaked at $5.05M in Q4 2021.
  • 75 funds tracked by Wall St. Rank held Lifecore Biomedical as of Q2 2024.

Based on Assenagon Asset Management's 13F filing for Q2 2024, filed 18 Jul 2024.